Within two to four weeks we find potential targets/biomarker candidates or do a detailed target/biomarker assessment. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll contact you to discuss next steps.

Use our platform to find novel target/biomarker candidates or do detailed target/biomarker assessment yourselves. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll set up a demo to show you!

Please contact me to discuss:

Subscription to Euretos AI Platform
Euretos consulting service
Direct access to Euretos API

Do you have a question on gene-disease associations that are not covered on this page? Or would you like to know more about the Euretos AI Platform? Please fill in your contact details and we will reach out to you!




Euretos AI Platform predicts key molecular mechanism for recently identified lung cancer target



Thursday 22 February 2018

In a recent study, published in the Oncotarget journal, researchers identified PRC1 as a novel potential target for lung cancer. The study found that tumorigenesis and cell proliferation strongly depend on PRC1 and inhibition of PRC1 significantly reduced lung tumor formation.

The underlying mechanism the researchers discovered was that depletion of PRC1 affected cytokinesis which resulted in a strong increase in polyploid bi- and multinuclear cells ultimately leading to apoptosis and cell senescence. This outcome was relatively surprising as PRC1 is known to regulate Wnt/ß-catenin signaling in cancer cells. However, the researchers found no evidence for a role of PRC1 in this pathway in lung cancer.

An in silico analysis using the Euretos AI Platform, shows that this mechanism could have been predicted. The platform provides a Gene-Disease function that analyses the genes that interact with PRC1 that are known to be associated with lung cancer. The cell & molecular dysfunction section of this function confirms the outcome of the publication:



















Figure 1: Cell & molecular dysfunction analysis showing key aspects of the molecular mechanism driving PRC1 involvement in lung cancer (source: Euretos AI Platform)

The analysis shows that PRC1 plays a central role in all the main processes identified in the publication such as cell proliferation, cell division, cytokinesis and cellular senescence:













Figure 2: Detailed list of key physiological processes driving PRC1 involvement in lung cancer (source: Euretos AI Platform)

The inhibition of PRC1, which is upregulated in many differential expression experiments for lung cancer, provides therefore a promising therapeutic approach for PRC1 driven types of lung cancer:


















Figure 3: Dysregulation analysis showing the upregulation of PRC1 in lung cancer and it’s interaction with other dysregulated proteins (source: Euretos AI Platform)

The full analysis is available on request via the contact form on the Euretos website or at information@euretos.com

Read more news articles: Euretos News

About this series - The purpose of the Euretos Research Note series is to provide a data analytics perspective on recent life sciences publications. The series focuses on two types of questions: (1) Did the available data already point in the direction of a discovery? (2) What further research angles does the available data suggest?